Behavioral neuropharmacology

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 4, Issue 1, 1998, Pages 26-35

  Zimmerman, Andrew W ^a,b   Jinnah, H A ^a   Lockhart, Paula J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

Autism; Behavior; Comorbidity; Developmental disabilities; Genotype; Lesch Nyhan disease; Mental retardation; Neuropharmacology; Phenotype; Reductionism

Indexed keywords

PSYCHOTROPIC AGENT;

AUTISM; BEHAVIOR DISORDER; DIAGNOSTIC ACCURACY; DISABILITY; FOLLOW UP; GENOTYPE; HYPOTHESIS; LESCH NYHAN SYNDROME; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DEFICIENCY; NEUROPHARMACOLOGY; NEUROTRANSMISSION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PURINE METABOLISM; REVIEW;

EID: 0031936675     PISSN: 10804013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2779(1998)4:1<26::AID-MRDD6>3.0.CO;2-V     Document Type: Review

References (42)

1. Angold A, Costello E. Depressive co-morbidity in children and adolescents: Empirical, theoretical and methodological issues. Am J Psychiatry 1993;150:1779-1791.
2. Benke PJ, Hebert A, Herrick N. In vitro effects of magnesium ions on mutant cells from patients with the Lesch-Nyhan syndrome. N Engl J Med 1973;289:446-450.
3. Biederman J, Newcorn J, Sprich S. Co-morbidity of attention deficit hyperactivity disorder with conduct, depression, anxiety and other disorders. Am J Psychiatry 1991;148:564-577.
4. Bird H, Gould M, Staghezza B. Pattern of diagnostic co-morbidity in a community sample of children aged 9-16 years. J Am Acad Child Adolesc Psychiatry 1993;32:361-368.
5. Breese GR, Criswell HE, Johnson KB, et al. Neonatal destruction of dopairunergic neurons. Neurotoxicology 1994;15:149-160.
6. Chugani DC, Musick O, Rothermel R, et al. Altered serotonin synthesis in dentatothalamocortical pathways in autistic boys. Ann Neurol 1997;42:666-669.
7. Cook E, Rowlett R, Jaselskis C, et al. Fluoxetine treatment of patients with autism and mental retardation. J Am Acad Child Adolesc Psychiatry 1992;31:739-745.
8. Cook EH, Courcheshne R, Lord C, et al. Evidence of linkage between the serotonin transporter and autistic disorder. Mol Psychiatry 1997;2: 247-250.
9. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. 7th ed. New York: Oxford, 1996:82-102.
10. Endres W, Helmig M, Shin YS, et al. Bone marrow transplantation in Lesch-Nyhan disease. J Inherit Metab Dis 1991;14:270-271.
11. Ernst M, Zametkin AJ, Matochik JA, et al. Presynaptic dopaminergic deficits in Lesch-Nyhan disease. N Engl J Med 1996;334:1568-1572.
12. Ferguson D, Horwood J, Lynskey M. Prevalence and co-morbidity of DSM IIIR diagnosis in a birth cohort of 15 year olds. J Am Acad Child Adolesc Psychiatry 1993;32:1127-1134.
13. Ghadimi H, Bhalla CK, Kirchenbaum DM. The significance of the deficiency state in Lesch-Nyhan syndrome. Acta Pediatr Scand 1970;59: 233-240.
14. Goleman D. Coming soon to a Prozac nation. The New York Times. Sunday, November 24, 1996.
15. Green WH. Child and Adolescent Clinical Psychopharmacology. 2nd ed. Baltimore: Williams & Wilkins, 1995.
16. Jankovic J, Caskey CT, Stout JT, et al. Lesch-Nyhan syndrome: A study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol 1988;23:466-469.
17. Jensen PS, Martin D, Cantwell D. Co-morbidity in ADHD. Implications for research, practice and DSM V. J Am Acad Child Adolesc Psychiatry 1997;36:1065-1079.
18. Jinnah HA, Breese GR. Animal models for Lesch-Nyhan disease. In: Iannocconne PM, Scarpelli DG, eds. Biological aspects of disease: Contributions from animal models. Amsterdam: Harwood Academic Publishers, 1997:93-143.
19. Kelley WN, Wyngaarden JB. Clinical syndromes associated with hypoxanthine guanine phosphoribosyltransferase deficiency. In: Stanbury JB, Wyngaarden JB, Frederickson DS, et al., eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 1983:1115-1143.
20. Karl PI, Kwun R, Slonim A, et al. Ethanol elevates fetal serum glutamate levels in the rat. Alcohol Clin Exp Res 1995;19:177-181.
21. Landa R, Martin M, Clark S. Evidence for specific impairment in sibs of autistic individuals. Proceedings of the Am Speech Lang Hear Assoc 1996;107.
22. Lloyd KG, Hornykiewicz O, Davidson L, et al. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Engl J Med 1981;305:1106-1111.
23. Manzke H, Gustmann H, Koke HB, et al. Hypoxanthine and tetrahydrobiopterin treatment of a patient with features of the Lesch-Nyhan syndrome. In: Nyhan WL, Thompson LF, Watts RWE, eds. Purine and Pyrimidine Metabolism in Man V. New York: Plenum Press, 1986:197-204.
24. Marks JF, Baurn J, Keele DK, et al. Lesch-Nyhan syndrome treated from the early neonatal period. Pediatrics 1968;42:357-359.
25. Mizuno T, Yugari Y. Self-mutilation in Lesch-Nyhan syndrome. Lancet 1974;1:761.
26. Nyhan WL, Parkman R, Page T, et al. Bone marrow transplantation in Lesch-Nyhan disease. In: Nyhan WL, Thompson LF, Watts RWE, eds. Purine and Pyrimidine Metabolism in Man V. New York: Plenum Press, 1986:167-170.
27. O'Brien G, Yule W. Behavioural Phenotypes. London: Mac Keith Press, 1995:1-23.
28. Page T, Nyhan WL. The spectrum of HPRT deficiency: An update. Adv Exp Med Biol 1989;253A:129-133.
29. Page T, Bakay B, Nissinen E, et al. Hypoxanthine-guanine phosphoribosyltranferase variants: Correlation of clinical phenotype with enzyme activity. J Inherit Metab Dis 1981;4:203-206.
30. Page T, Barshop B, Yu AL, et al. Treatment of Lesch-Nyhan syndrome with AICAR. In: Sahota A, Taylor M, eds. Purine and Pyrimidine Metabolism in Man VIII. New York: Plenum Press, 1995:353-356.
31. Palmour RM. Animal models for Lesch-Nyhan disease. In: Boulton A, Baker G, Butterworth R, eds. Animal Models of Neurological Disease I. Humana Press, 1992:295-353,
32. Roach ES, Delgado M, Anderson L, et al. Carbarnazepine trial for Lesch-Nyhan self-mutilation. J Child Neurol 1996;11:476-478.
33. Rossiter BJF, Caskey CT. Hypoxanthine-guanine phosphoribosyltransferase deficiency: Lesch-Nyhan syndrome and gout. In: Scriver CR, Beaudet AL, Sly WS, et al. eds. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill, 1995: 1679-1706.
34. Schulman JD, Greene ML, Fujimoto WY, et al. Adenine therapy for Lesch-Nyhan syndrome. Pediatr Res 1971;5:77-82.
35. Sege-Peterson K, Nyhan WL, Page T. Lesch-Nyhan disease and HPRT deficiency. In: Rosenberg RN, Prusiner SB, DiMauro S, et al., eds. The Molecular and Genetic Basis of Neurological Disease. Boston: Butterworth-Heinemann, 1992:241-260.
36. Streissguth AP, Aase JM, Clarren SK et al. Fetal alcohol syndrome in adolescents and adults. JAMA 1991;265:1961-1967.
37. Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry 1995;152:332-340.
38. Watts RWE, McKeran RO, Brown E, et al. Clinical and biochemical studies on treatment of Lesch-Nyhan syndrome. Arch Dis Child 1974;49:693-702.
39. Watts R. WE, Spellacy E, Gibbs DA, et al. Clinical, post-mortem, biochemical and therapeutic observations on the Lesch-Nyhan syndrome with particular reference to the neurological manifestations. QuartJ Med 1982;201:43-78.
40. Williams N. Biologists cut reductionist approach down to size. Science 1997;277:476-477.
41. Wong DF, Harris JC, Naidu S, et al. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Natl Acad Sci USA 1996;93:5539-5543.
42. Zimmerman AW, Frye VH, Potter NT. Immunological aspects of autism. Int Pediatr 1993;8: 199-204